Latest Earnings Results: Q3 '26
Estimated EPS
$1.90
Reported EPS
$3.25
Surprise
+70.96%
Estimated Rev
$1.76B
Reported Rev
$1.89B
Surprise
+7.48%
BeOne Medicines expects operating cash flows and existing cash and cash equivalents to fund expenses and planned long-term investments for at least 12 months; approximately $258.8M of bank loans is due within 12 months.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | $3.76 | -- | -- | N/A |
Q3 '26 | $1.90 | $3.25 | 70.96% | BEAT |
Q2 '26 | $1.93 | $2.05 | 6.35% | BEAT |
Q1 '26 | $1.73 | $1.96 | 13.07% | BEAT |
Q4 '25 | $1.21 | $0.60 | -50.28% | MISSED |